Speakers

Expand/Collapse

Luke Lee
CEO, Co-Founder
3T Biosciences

Day One

Thursday 13th December 2018

8:40 am | Industry Panel to Address the Most Critical Questions for this Nascent & Emerging Therapeutic

Focus Day

12:20 pm | Designing Best in Class TCR Cell Therapies Against Novel Antigens

Melanie Patterson
Principal Research Scientist II
Abbvie

Geoffrey Lynn
CEO
Avidea Technologies

Maren Lang
Head of Bioinformatics Research & Development
BioNTech SE

Stephen Albert Johnston
CEO
Calviri, Inc

Day Two

Thursday 13th December 2018

1:50 pm | Exploring an Additional, Unrecognised Source of Tumour Neoantigens for Off-the-Shelf Therapeutic Vaccines

Ray Jupp
Chief Scientific Officer
Ervaxx LTD

Jens Kringelum
Director, Genomic Immuno-Oncology
Exaxion Biotech

Wigard Kloosterman
Chief Scientific Officer
Frame Cancer Therapeutics

Day One

Thursday 13th December 2018

5:00 pm | Trailblazing the Development of Off-the Shelf Anti-Cancer Vaccines

Robin Fahraeus
Head of Research Group
French National Institute of Health and Medical Research (INSERM)

Day Two

Thursday 13th December 2018

2:50 pm | Developing Innovative Targets & Control Points for Immunotherapy Based on Neoantigens

Jennie Lill
Senior Director of Proteomics & NGS
Genentech

Focus Day

11:40 am | Engineered T cells for the Treatment of Malignancy

Narinder Singh
Senior Vice President, Pharmaceutical Sciences & Manufacturing
Genocea

Day Two

Thursday 13th December 2018

2:20 pm | Key Considerations & Strategies for Technical Development of Personalised Neoantigen-based Cancer Vaccine and T-Cell Therapy

Jessica Flechtner
CSO
Genocea

Day Two

Thursday 13th December 2018

9:10 am | The Impact of Stimulatory & Inhibitory Neoantigens Selected with the ATLAS Bioassay: Clinical & Pre-Clinical Results

Andrew Allen
CEO
Gritstone

Day One

Thursday 13th December 2018

9:20 am | Personalised Neoantigen Immunotherapy – Demonstrating Priming of CD8+ T cell Responses is a Key Step

8:40 am | Industry Panel to Address the Most Critical Questions for this Nascent & Emerging Therapeutic

Jeff Hutchin
CSO, COO
Heat Biologics

Day Two

Thursday 13th December 2018

4:30 pm | The Use of Dermal Cancer Testis Antigen Delivery & T Cell Co-stimulation as a Neoantigen Approach in Allogenic Cell Therapy in Cancer

Gerben Zondag
CEO
Immunetune

Lei Zheng
Associate Professor
John Hopkins School of Medicine

Alexandre Harari
Group leader, Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne

Carla Herberts
Senior Clinical Assessor & CAT member
Medicines Evaluation Board

Focus Day

2:20 pm | Learning from the Past and the CAR-T Cell Therapy Field – A Regulatory Perspective

Dolores Schendel
CEO
Medigene

Focus Day

1:50 pm | Accelerating Neoantigen Based TCR Therapy to the Clinic

John Johnston
Clinical Assessor
MHRA

Day Two

Thursday 13th December 2018

9:50 am | Outlining the Key Considerations to Take into Account When Interacting with a Regulatory Body

TJ Langer
CEO & President
Myst Therapeutics

Joost van den Berg
Head of facility – Pharmacist
Netherlands Cancer Institute

Focus Day

10:10 am | Leveraging Neoantigens for Personalised TCR Gene Therapy

Elisa Scarselli
Chief Scientific Officer, Chief Medical Officer & Co-founder
Nouscom

Day Two

Thursday 13th December 2018

5:00 pm | How Nouscom Viral Vectored Vaccines Encoding Many Neoantigens Synergize With Immunotherapies Reverting Tumour Immune Suppression

Trevor Clancy
CSO & Co-founder
OncoImmunity

Day One

Thursday 13th December 2018

9:50 am | An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens

Antonella Vitiello
CEO & Co-Founder
Persimmune

Tamara Ouspenskaia
Postdoctoral Fellow
Postdoctoral Fellow Broad Institute

Sean Boyle
Senior Director, Bioinformatics Applications
Personalis

Day One

Thursday 13th December 2018

4:30 pm | ImmunoID NeXT: A Comprehensive Platform for Improving Neoantigen Prediction, Tumour Escape Mechanism Reporting, TME Assessment, & Tumor Heterogeneity Profiling for Immuno-Oncology

Philip Arlen
Chief Executive Officer, Chief Medical Officer
Precision Biologics

Pia Kvistborg
Junior group leader, Department of Immunology
The Netherlands Cancer Institute

Focus Day

9:40 am | Delving into the Properties of T-Cell Recognised Neoantigens

Kaidre Bendjama
Project Leader, Personalized Cancer Vaccines
Transgene

Eniko R Toke
Chief Scientific Officer
Treos Bio

Day One

Thursday 13th December 2018

5:30 pm | A Personal Antigen Selection Calculator (PASCal) for the Design of Off-The-Shelf, Shared NeoantigenBasedPersonal Vaccines

Nicola Ternette
Head of Immunopeptidomics
University of Oxford

Sara Mangsbo
Associate Professor
Uppsala University Sweden

Agnete Fredriksen
President & Chief Scientific Officer
Vaccibody

Day Two

Thursday 13th December 2018

8:40 am | Vaccibody’s Clinical Study - The Importance of Different Vaccine Platforms, Neoepitope Selection & Clinical Trial design to Show Vaccine-induced Clinical Efficacy

Alena Gros
Principal Investigator, Tumor Immunology & Immunotherapy
Vall d’Hebron Institute of Oncology

Focus Day

9:10 am | Novel Approaches for More Effective Neoantigen Identification

Sari Pesonen
Head of R&D
Valo Therapeutics

Heinz Lubenau
Chief Operating Officer & Co-Founder
Vaximm

Kostas Kosmatopoulos
CEO
Vaxon Biotech

Russell Pachynski
Assistant Professor, Division of Oncology
Washington University School of Medicine

Sean Michael Boyle
Sr. Director, Bioinformatics Applications
Personalis, Inc.